These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 30540648)

  • 41. Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study.
    Kwon S; Lee SR; Choi EK; Lee KY; Choi J; Ahn HJ; Oh S; Lip GYH
    Vasc Health Risk Manag; 2024; 20():231-244. PubMed ID: 38774425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study.
    Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
    Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

  • 45. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
    Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
    Fazio G; Squizzato A; Mazzetti M; Mannarini A; Fischetti A; Colonna P
    G Ital Cardiol (Rome); 2021 Jan; 22(1):70-79. PubMed ID: 33470246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
    Monteiro P
    Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
    Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
    J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.
    Rago A; Papa AA; Attena E; Parisi V; Golino P; Nigro G; Russo V
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1003-1007. PubMed ID: 32946035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
    Chao TF; Hong KS; Lee BC; De Caterina R; Kirchhof P; Reimitz PE; Chen C; Unverdorben M; Wang CC
    J Chin Med Assoc; 2021 May; 84(5):485-490. PubMed ID: 33742992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
    Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
    Vilain KA; Yang MC; Hui Tan EC; Wang K; Li H; Hsu WH; Giugliano RP; Cohen DJ; Magnuson EA;
    Value Health Reg Issues; 2017 May; 12():74-83. PubMed ID: 28648320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
    Wilkinson C; Wu J; Searle SD; Todd O; Hall M; Kunadian V; Clegg A; Rockwood K; Gale CP
    BMC Med; 2020 Dec; 18(1):401. PubMed ID: 33357217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
    Cohen AT; Ay C; Hainaut P; Décousus H; Hoffmann U; Gaine S; Coppens M; da Silva PM; Castro DJ; Amann-Vesti B; Brüggenjürgen B; Levy P; Bastida JL; Vicaut E; Laeis P; Fronk EM; Zierhut W; Malzer T; Bramlage P; Agnelli G;
    Thromb J; 2018; 16():9. PubMed ID: 29719492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.